Received Feb 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
He reports being lethargic and achy.; He reports being lethargic and achy.; This non-serious case was reported by a consumer via call center representative and described the occurrence of lethargy in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On 02-FEB-2026, the patient received the 1st dose of Shingrix. In FEB-2026, an unknown time after receiving Shingrix, the patient experienced lethargy (Verbatim: He reports being lethargic and achy.) and pain (Verbatim: He reports being lethargic and achy.). The outcome of the lethargy and pain were unknown. It was unknown if the reporter considered the lethargy and pain to be related to Shingrix. It was unknown if the company considered the lethargy and pain to be related to Shingrix. Additional Information: GSK Receipt Date: 03-FEB-2026 The batch number was not provided and a request for this information has been made.